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Abstract 
 
Introduction: Quality of life for brain tumour patients has become an important outcome 
measure as patient perspectives can evaluate the impact of a diagnosis or treatment. Brain 
tumour patients experience participation restriction in completing these questionnaires due to 
multiple factors. The purpose of this literature review was to elicit the factors that influence the 
clinical utility of HRQoL questionnaires in brain tumour patients. 
 
Method: A literature search was conducted on March and October 2018 using the following 
electronic databases: MEDLINE, EMBASE, and CINAHL. Papers with a publication date 
between 1998 and 2018 were sought to identify literature that discussed the characteristics of 
HRQoL questionnaires (EORTC QLQ C-30 and BN20, FACT-Br, and SF-36 Health Survey), its 
use with brain tumour patients, clinical utility, and factors contributing to its non-completion. 
 
Findings: Methodological and patient-related factors in clinical trials that have contributed to 
non-completion of HRQoL questionnaires in brain tumour patients were identified. Studies have 
identified important factors that contribute the clinical usefulness of HRQoL questionnaires such 
as relevance of information, ability to highlight concerns, time to complete and interpret data. 
 
Conclusion: At present, there is no gold standard tool that measures quality of life for brain 
tumour patients. Limited studies evaluate the use of HRQoL questionnaires in brain tumour 
patients in clinical contexts. Therefore, factors that contribute to clinical utility of HRQoL 
questionnaires for brain tumour patients facilitated development of criteria to be investigated in a 
feasibility study to compare three commonly used HRQOL questionnaires. 
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SECTION 1: LITERATURE REVIEW 
 
Measuring Quality of Life Following 
Neurosurgical Treatment for Brain  
Tumour Patients: a Literature Review 
 
 
Keyword: Quality of Life, Brain Tumour, patient perspectives, participation  
 
 
1. Introduction of topic 
In 2008, the prevalence of primary brain tumours in Australia was 11.3 cases per 100,000 
(Dobes et al., 2011). 93% of primary brain tumours were represented in adults aged ≥ 20 years 
old, where 42% of these tumours were diagnosed as malignant (Dobes et al., 2011). Although 
primary brain tumours present to have fairly low incidence rates compared to other cancers, such 
as breast and lung cancer, malignant brain tumours are associated with high morbidity and 
mortality (Kamangar, Dores, & Anderson, 2006; Wen & Kesari, 2008). Advancement in anti-
cancer treatment, involving neurosurgery, radiotherapy, and chemotherapy, still pose risks of 
severe side effects (King et al., 2016; Taphoorn et al., 2005). Therefore, there has been an 
emphasis in using clinical endpoints that look beyond a patient’s overall survival and to measure 
the quality of life (Efficace & Bottomley, 2002).  Acquiring patient perspectives through health-
related quality of life questionnaires (HRQoL) questionnaires aim to manage the risks that come 
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with anti-cancer treatments and its possible detrimental effects on a patient’s health and well-
being for the duration of his/her life span (Efficace & Bottomley, 2002).   
HRQoL questionnaires are subjective measurements that evaluate a person’s functional, 
psychological, and social well-being (Yavas et al., 2012). It obtains patient perspectives in their 
health and well-being in order to assist clinicians in developing a more effective treatment plan 
(King et al., 2016). These tools are used with cancer patients as it can facilitate assessment of 
treatment needs, evaluation of treatment outcome, and prediction of response to future treatment 
(Cella & Tulsky, 1993). This takes a client-centered approach as it highlights patients’ concerns 
and provides health care professionals information that can facilitate development of more 
effective treatment plans that best suit patients’ needs (King et al., 2016). These potential 
outcomes are important as it can provide better health outcomes.   
Three common HRQoL questionnaires used for brain tumour patients are the European 
Organization for Cancer and Treatment of Cancer (EORTC) Quality of Life Questionnaire 
(QLQ-C30) (Aaronson et al., 1993); the Functional Assessment of Cancer Therapy-General 
(FACT-G) (Cella et al., 1993); and the 36-Item Short Form (SF-36) Health Survey (Ware & 
Sherbourne, 1992). EORTC QLQ-BN20 (Osoba et al., 1996) and FACT-Br (Weitzner et al., 
1995) are brain-specific modules developed to complement their core questionnaires (EORTC 
QLQ C-30 and FACT-G) by adding questions that pertain more to brain tumour patients. These 
questionnaires are widely used and have been tested for validity and reliability for brain tumour 
patients (Bunevicius, 2017; Osoba et al., 1996; Weitzner et al., 1995). They highlight symptoms, 
emotional, physiological, social concerns specific to brain tumour patients in order to obtain 
valuable patient perspectives that may inform clinicians how a diagnosis or a treatment have 
influenced a patient’s quality of life.      
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Despite the advantages HRQoL questionnaires can provide clinical trials, multiple 
challenges have impeded successful use of HRQoL measures in the brain tumour population. 
Studies have identified methodological and patient-related factors that may be contributing to 
failed completion of HRQoL questionnaires, such as lack of staff, clinician attitudes, patient 
motivation, timing of the assessments, and misinterpretation of question (Dirven et al., 2013; 
King et al., 2016; Walker et al., 2003). In addition to that, several studies have also investigated 
difficulties health care professionals have in using HRQoL questionnaires (Berry et al., 2011; 
King et al., 2016). At present, there is no gold standard tool that measures quality of life for brain 
tumour patients (Dirven et al., 2013). This study therefore proposes to investigate the feasibility 
of comparing three commonly used HRQoL questionnaires (EORTC QLQ C-30 and BN20, 
FACT-Br, and SF-36 Health Survey) to identify the most effective and efficient tool for brain 
tumour patients undergoing neurosurgical treatment. 
In order to understand these issues, a literature review on HRQoL questionnaires for 
brain tumour patients was conducted. This review aims to investigate differences in the 
commonly used HRQoL questionnaires, methodological, and patient-related factors brain tumour 
patients experience, barriers contributing to participation restriction of completing HRQoL 
questionnaires. It also aims to explore health care professionals’ perspectives and attitudes 
toward administering these questionnaires in order to identify possible barriers and enablers in 
the clinical utility of HRQoL questionnaires with brain tumour patients undergoing neurosurgical 
treatment. This review examines the existing literature on the clinical usefulness of HRQoL 
questionnaires to identify factors that may contribute to increasing participation when acquiring 
HRQoL data. Identifying an effective and efficient tool for brain tumour patients undergoing 
neurosurgical treatment can facilitate completion of questionnaires. This is crucial to better 
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health outcomes as it acquires patient perspectives that inform health care professionals how 
treatment affects a patient’s quality of life. 
For the purpose of this study, reference to FACT-Br includes FACT-G, the core 
questionnaire. The theoretical framework International Classification of Functioning, Disability, 
and Health (ICF) (Vargus-Adams & Majnemer, 2014) is also explored to understand how the 
different factors mentioned above influence brain tumour patients’ participation in completing 
HRQoL questionnaires.  
1.1 Search strategy used 
Three online databases were used to search: MEDLINE, EMBASE, and CINAHL. The 
keywords used to search these engines were the following: “quality of life” AND “brain 
tumo?r*” AND “Short Form 36” or “36-Item Short Form Survey” or “EORTC QLQ-BN20” or 
“European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 
Brain Cancer” or “FACT-Br” or “Functional Assessment of Cancer Therapy – Brain”. These key 
terms were used in the English language and only studies in English were screened. This search 
produced high amounts of duplicates, which were removed. Titles and abstracts were screened in 
order to remove literature that was not relevant for this study. Literature on the following topics 
were excluded: pediatrics, quality of life of patient-proxies, effectiveness of anti-cancer 
treatments, perinatal risks, and Ginko biloba.  
2. International Classification of Functioning, Disability, and Health (ICF)  
 The International Classification of Functioning, Disability, and Health (ICF) is a 
biopsychosocial framework in which facilitates communication between health care 
professionals in a multidisciplinary team to describe persons’ function and health (Cieza & 
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Stucki, 2005). ICF considers factors beyond bodily functions such as health condition, personal, 
and environmental factors that may be influencing patients’ participation in an activity. WHO 
(2001) describes the domains “Activities and Participation” as having two qualifiers which 
consists of performance and capacity. Performance qualifier evaluates how an individual is 
functioning within their environment, which includes their physical, social, and attitudinal 
contexts. Capacity qualifier describes a person’s ability to execute an action. This is measured in 
a standard environment, in which exhibits how a person can adapt to their environment. Figure 1 
demonstrates the interdependence of the ICF domains.  
    The interdependence of environmental factors, personal factors, activities, body 
functions and structures are used as a framework to understand participation restriction brain 
tumour patients experience when completing HRQoL questionnaires (activity) in a clinical 
context. The use of this framework allows for the consideration of the standard environment in 
which brain tumour patients need to complete HRQoL questionnaires, while understanding their 
capacity qualifier to execute the activity, in order to facilitate participation. This will be explored 
in the next sections.  
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                           Figure 1. The International Classification of Functioning, Disability, and Health. 
                          Adapted from Vargus-Adams, J. N., & Majnemer, A. (2014). International classification          
                              of functioning, disability and health (ICF) as a framework for change: Revolutionizing              
                               rehabilitation. Journal of Child Neurology, 29(8), 1030-1035.                    
                               doi:10.1177/0883073814533595 
 
 
3. Differences in HRQoL Questionnaires  
 FACT-Br, EORTC QLQ C-30 and BN20, and SF-36 Health Survey have various 
characteristics and means of presenting well-being. A comparison of the characteristics found in 
these HRQoL questionnaires are presented in Table 1. EORTC QLQ C-30 and QLQ BN20 
assess more functional concerns, as this questionnaire lists 37 out of 50 items specific to this 
issue (Chow et al., 2014). A study by King, Bell, Costa, Butow, and Oh (2014) compared the 
responsiveness of FACT-G and EORTC QLQ C-30 in important clinical effects found in a 
heterogenous group of cancer patients (n=162). The study found EORTC QLQ C-30 to have 
significantly larger responsive index when assessing for social health domain. This subscale 
explores how physical condition or medical treatment has interfered with both family life and 
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social activities. This may assist clinicians who may be prioritizing functional endpoints and 
evaluating how a treatment or diagnosis have influenced a patient’s quality of life. 
 FACT-Br, which includes FACT- G core questionnaire, addresses more emotional and 
social issues (Chow et al., 2014). This may be important to brain tumour patients as the diagnosis 
of malignant brain tumour also affect their families and communities. A descriptive study by  
Bradley et al. (2007) explored the financial impact primary malignant brain tumour patients 
experience during treatment and reported of common themes patients stated. Twenty participants 
reported concerns with the costs associated with medication and healthcare, its negative impact 
on their family, costs of their disability, and uncertainty for the future. This study highlighted 
some of the emotional and social concerns brain tumour patients experience as some patients 
transition to relying on family and/or friends for financial support. This was further explored in a 
prospective longitudinal study by Bradley et al. (2009), where family caregivers report feeling 
abandoned when caring for patients with high levels of neuropsychological function. This 
suggests that caregivers of higher functioning patients do not receive as much support from 
family and friends due to patients presenting to be well. Therefore, friends and family may not 
perceive support as being necessary for the caregiver. These perspectives are essential in 
understanding the changes brain tumour patients and their family and friends may be 
experiencing in order to secure proper support during treatment to alleviate social and emotional 
burden patients and their families may experience. Therefore, using HRQoL questionnaires such 
as FACT-Br, may provide more information on the impact the treatment or the disease has had 
on the patients’ emotional and social health domains of well-being. This can facilitate 
discussions around these concerns, which health professionals can utilise to organise proper 
support to meet the patients’ needs.  
Page 13 of 27 
 
SF-36 Health Survey evaluates patient perceptions on broad physical and emotional 
health domains (Ware & Sherbourne, 1992). The test for validity and reliability were completed 
on a heterogenous group of patients who have not received adjuvant therapies (Bunevicius, 
2017). The SF-36 Health Survey has shown to have ceiling and floor effects for the subscales 
under role limitations and emotional functioning, which signifies its low sensitivity for 
functional and emotional functioning in brain tumour patients (Bunevicius, 2017). General 
questionnaires, such as SF-36 Health Survey, also do not evaluate all areas of well-being and 
functioning specific to brain tumour patients. However, SF-36 Health Survey assesses how a 
brain tumour influences broad domains of impairment, which can then be compared with 
HRQoL across the general population with different disorders (Bunevicius, 2017). In addition to 
that, SF-36 Health Survey is a general HRQoL questionnaire, which is typically more familiar to 
health care professionals as these questionnaires are typically used across oncology settings 
(King et al., 2016).  
FACT-Br, EORTC QLQ C30 and BN20, and SF-36 Health Survey emphasize well-being 
in different ways and can be chosen as the appropriate tool depending on what the clinician 
and/or researcher need to evaluate. FACT-Br enables clinicians to acquire more social and 
emotional issues from brain tumour patients. EORTC QLQ C-30 and BN20 are able to evaluate 
more of brain tumour patients’ functional concerns. SF-36 Health Survey allows for a broader 
assessment of health domains that enable clinicians to compare brain tumour patients’ concerns 
to the general population. Each of these HRQoL questionnaires acquire valuable patient 
perspectives and may inform clinicians how a diagnosis or treatment have influenced a patient’s 
quality of life. This can serve as a tool to facilitate better communication between patient and 
physician to provide feedback and plan for treatment plans that best suit patient needs. 
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Table 1. Characteristics of EORTC QLQ- C30 and BN20, FACT-Br, and SF-36 Health Survey 
  
EORTC QLQ-C30 and 
BN20 
 
 
FACT-Br 
 
SF-36 Health 
Survey 
 
 
 
 
Validity 
 
 
 
Construct for primary 
brain neoplasms 
(Taphoorn, Claassens, et 
al., 2010) 
 
Convergent for primary 
brain neoplasms 
(Weitzner et al., 1995) 
 
Content for brain 
metastases (Chen et al., 
2014) 
 
 
 
 
Criterion for 
primary brain 
tumour  
(Bunevicius, 2017) 
 
Reliability 
 
 + 
 
 + 
 
 
+ 
 
 
Core 
Questionnaire 
Domains 
 
physical function, 
emotional function, pain, 
fatigue, appetite, dyspnea, 
constipation, sleep, global 
QoL 
 
 
 
physical function, 
social/family, emotional, 
functional well-being 
 
 
 
 
 
 
 
physical function, 
social functioning, 
role limitation (due 
to physical 
problems), mental 
health, vitality, 
pain, general health 
perception 
 
 
 
Brain-specific 
Subscales 
 
future uncertainty, visual 
disorder, motor 
dysfunction, 
communication deficit, 
brain specific symptoms 
(e.g. seizures, headaches, 
weakness of legs) 
 
 
concentration, memory 
seizures, eyesight, 
hearing, speech, 
personality, expression of 
thoughts, weakness, 
coordination, headaches  
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4. Health Care Professionals  
 HRQoL questionnaires aim to increase awareness in a patients’ physical, social, and 
psychological well-being in order to assess how a treatment or diagnosis have affected their 
overall health. A randomized controlled trial by Detmar, Muller, Schornagel, Wever, and 
Aaronson (2002) showed that the intervention group, who used HRQoL questionnaires, had an 
increase of at least 10% in physician awareness of patients’ concerns in regards to pain, fatigue, 
daily activities, social activities, and feelings. This finding was not statistically significant from 
the control group. However, 97% of patients in the intervention group reported that the HRQoL 
summary provided to physicians were an accurate depiction of their functioning and well-being. 
This is crucial to patient-physician communication as 79% of the participants also believed that 
the HRQoL summary enhanced their clinicians’ recognition of their health problems. In addition, 
physicians in this study reported that the HRQoL summary facilitated communication in regards 
to psychosocial issues and unexpected symptoms. Similarly, a randomized trial by Berry et al. 
(2011) demonstrated there was no significant difference between the control group and the 
intervention group, who had HRQoL summary provided to clinicians. However, some clinicians 
in this study (n=113) responded to a questionnaire, where 64.4% of the clinicians reported that 
the HRQoL summary facilitated their interview and 53.6% agreed the HRQoL data assisted in 
identifying areas of referral. These studies may not have demonstrated direct correlation between 
HRQoL summaries and patient-physician communication. However, it has exhibited clinicians’ 
attitude towards the usefulness of HRQoL questionnaires.  
Despite the potential advantages HRQoL questionnaires can provide patient-physician 
communication, it is limited by attitudes toward focusing on physical concerns. A study by 
Lauzon et al. (2013) assessed health care professionals’ perspectives on which HRQoL issues 
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were most relevant to patients with brain metastases using the FACT-Br. This study reported that 
health care professionals tend to prioritize issues concerning physical manifestations over 
psychosocial concerns. Similarly, another study by Detmar, Aaronson, Wever, Muller, and 
Schornagel (2000) surveyed oncologists to evaluate their attitude on HRQoL concerns and 
patients’ characteristics. This study found oncologists highlighting physical aspects of patients’ 
health as they found physical concerns to be their responsibility. However, in order to obtain a 
comprehensive understanding of a patients’ health and well-being, health care professionals need 
to address both physical and psychosocial health domains (Lauzon et al., 2013).  
5. Factors Related to Non-Completion of HRQoL Measures  
Research has shown that there is a significant issue of incompletion of HRQoL 
questionnaires in the brain tumour population (Leung et al., 2014; Tsay, Chang, Yates, Lin, & 
Liang, 2012). Studies have investigated methodological and patient-related factors contributing 
to failed completion of HRQoL questionnaires (Dirven et al., 2013; S. King et al., 2016). The 
following subsections investigates these issues.  
5.1 Methodological factors  
A prospective study with malignant glioma patients by Walker et al. (2003) investigated 
the reasons for their high amounts of missing data for their HRQoL measures. This study found 
that their greatest cause of missing data was due to administrative failure, which had an average 
of 72.2% of their case. The administrative factors consisted of administering the HRQoL 
questionnaire the wrong time. This study suggested that providing the questionnaires at the 
incorrect time can prevent successful HRQoL data collection due to little explanation provided to 
patients and therefore affect the completion or accuracy of the HRQoL data. In addition to that, 
Dirven et al. (2013) emphasized the importance of correct timing when a HRQoL questionnaire 
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is administered due to the impact time has on the interpretation of HRQoL data. This was 
demonstrated in a retrospective study by Hakamies‐Blomqvist et al. (2001) where findings 
showed a statistical significance in the difference of HRQoL mean scores between the correct 
and incorrect time the questionnaire was administered. This suggested that incorrect timing of 
HRQoL questionnaires in oncological trials can produce unreliable measures and validity of QoL 
outcomes after a treatment.  
Limited time can also play an important role in the administration and interpretation of 
HRQoL questionnaires. A study by King et al. (2016) interviewed professionals experienced in 
either quality of life and/or brain cancer research where they reported issues in lack of time to 
administer and interpret the HRQoL questionnaires. This was further explored in a feasibility 
study by Snyder et al. (2013) where clinicians’ attitudes in the use of HRQoL questionnaires 
through a Patient Viewpoint website were investigated.  Clinicians report of the difficulties they 
experience in translating HRQoL scores and needing further explanation on what HRQoL item 
content and score mean.  
Methodological factors such as administrative issues, time of assessment, and 
interpretation of data have shown to contribute to incompletion and unsuccessful use of HRQoL 
data. Administrative factors such as, instructions provided to patients and time of assessment, 
affect the reliability and validity of the measures. Therefore, sufficient training of staff and a 
specific time window of when assessments are given, should be implemented in order to acquire 
accurate HRQoL measures (Dirven et al., 2013). Providing training or support for clinicians can 
also facilitate interpretation of patients’ responses in HRQoL questionnaires (King et al., 2016). 
Incorrect timing of assessment and lack of support to successfully interpret HRQoL measures 
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serve as barriers in the usefulness of HRQoL questionnaires as these factors can affect measures 
produced.  
 
5.2 Patient-related factors  
 Patient related factors consist of patient motivation, misunderstanding of questions, and 
incorrect completion of questions (Dirven et al., 2013). However, these factors can be addressed 
by methodological factors mentioned above. Walker et al. (2003) highlighted the importance of 
having trained individuals to administer HRQoL questionnaires in order to provide full 
explanation of the importance and correct use of these questionnaires. Other studies have agreed 
that patient related factors are less problematic than methodological factors (Bernhard, Gusset, & 
Hürny, 1998; Moinpour & Lovato, 1998). This stayed consistent with the findings in the study 
that assessed practical problems with quality of life assessments in patients with malignant 
glioma (Walker et al., 2003). As mentioned earlier, 72.2% of missing data was due to 
administrative failure, where only 6.1% of it is due to patient refusal. Another longitudinal study 
by Ahlner-Elmqvist et al. (2009) evaluated patients with malignant disease (n=297) to 
investigate non-compliance in the completion of HRQoL questionnaires and found most of their 
participants able to complete questionnaires until death. This study suggested that having family 
or caregiver support when completing questionnaires may facilitate compliance. However, this 
study did not include all of potential participants that met eligibility criteria in the original study. 
The complete group of participants are demonstrated in the study by Ahlner-Elmqvist et al. 
(2008) where additional participants (n=180) with malignant tumours did not participate in the 
study due to more advanced diseases and were closer to death. This suggests that the evaluation 
made of the incompletion of HRQoL questionnaires was due to a positive bias. Therefore, the 
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other participants who were not able to participate due to more advanced disease were not 
represented.  
 
6. Neurocognitive deficits  
 Brain tumour is a disease characterized by severe symptoms and are often influenced by 
both tumour and anti-cancer treatments (Reijneveld, Sitskoorn, Klein, Nuyen, & Taphoorn, 
2001; Taphoorn, Sizoo, & Bottomley, 2010). These pose risks of fatigue, anxiety, depression, 
and neurocognitive deficits (Boele et al., 2014; Mainio, Hakko, Niemelä, Koivukangas, & 
Räsänen, 2005; Struik et al., 2009). Cognitive dysfunction can affect an individual’s language, 
memory, attention, executive functions, and speed of information processing which may 
ultimately decrease a person’s functional independence. This impairment becomes a disability 
that can affect return to work, interpersonal relationships, and leisure activities (Zucchella, 
Bartolo, Di Lorenzo, Villani, & Pace, 2013). Apart from this being associated with negatively 
affecting quality of life, neurocognitive deficits may also prevent accurate patient-reported 
outcomes through HRQoL questionnaires (Ediebah et al., 2017). These patients are often 
excluded from clinical trials as evaluation of their HRQoL data may produce bias. As a result, 
HRQoL data are usually acquired in conjunction with HRQoL estimates provided by a patient’s 
proxy, also known as a partner, close relative, or friend.  
 HRQoL is a subjective measure, typically obtained through self-reports, as it is viewed 
that patients are the best judge of their quality of life (Yavas et al., 2012). However, gathering 
proxy estimates of a patient’s HRQoL may be required when a patient’s self-report is absent or 
unreliable (King et al., 2016). A cross-sectional study done by Ediebah et al. (2017) compared 
patient and patient by proxy HRQoL data in low-grade glioma patients (n= 246) who were 
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disease-free for at least one year following diagnosis and primary treatment. This study found 
that patient and patient by proxy ratings shared similar scores on HRQoL scales in SF-36 Health 
Survey and EORTC QLQ-BN20 except for physical functioning and symptoms scales found in 
the questionnaires (e.g. physical functioning, communication deficit, visual disorder). This study 
also found that the scores in best agreement between the patient and patient by proxy were 
physical and emotional concerns affecting one’s role. However, the findings of this study also 
showed statistically significant differences between patient (with cognitive impairment) and 
patient by proxy responses on scales measuring visual disorder, headaches, itchy skin, and 
bladder control. This study suggests that patient with low grade glioma and patient by proxy 
HRQoL scores generally have high levels of agreement. However, patients with neurocognitive 
deficits tend to have lower levels of agreement with patient by proxy ratings of HRQoL scores. 
Good patient and proxy agreement stayed consistent with a previous study by Giesinger et al. 
(2009) that investigated the level of agreement between patients with primary brain tumours and 
their proxy when rating patients’ HRQoL and symptoms. This study found good rater agreement 
between the patient and proxy for most physical symptoms (e.g. physical functioning, sleeping 
disturbances, appetite loss, constipation, financial impact). Lower agreements were found on 
social and psychological aspects (e.g. social functioning, cognitive functioning, emotional 
functioning, fatigue, pain, seizures). This study suggests that despite some differences in patient 
and proxy rating of patients’ HRQoL measures, including proxy rating is a feasible strategy to 
obtain information about a patient’s quality of life and symptom burden if patients are unable to 
provide the information themselves.  
 The discrepancies between patient and proxy ratings have produced different views in its 
usefulness as it has the potential to produce inaccurate and biased data (Kommer et al., 1997). 
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However, some may argue that when neurocognitive dysfunction starts to impact accuracy of 
HRQoL measurements, taking proxy reported HRQoL ratings may be considered as the most 
reliable information on patients’ quality of life (Ediebah et al., 2017). This can facilitate 
improving accuracy of HRQoL data for patients with cognitive deficits or reduction of missing 
data when acquiring HRQoL questionnaires (Dirven et al., 2013). However, the use of proxies to 
obtain HRQoL questionnaires need to differentiate between proxy-patient (from patient’s 
viewpoint) or proxy-proxy (from proxy’s viewpoint) perspective that is being represented in 
HRQoL measures due to possible differences between the two.  
 
7. Clinical Usefulness  
 HRQoL questionnaires have become important measures for brain tumour patients as it 
acquires patient perspectives on how a treatment or diagnosis have affected the patient’s quality 
of life. Studies have demonstrated the increase use HRQoL questionnaires with brain tumour 
patients in clinical trials, however there has been limited use in clinical contexts (King et al., 
2016). Barriers to routine clinical use need to be investigated to understand possible factors that 
may be contributing to its limited use. Chen, Li, and Kochen (2005) describes a HRQoL measure 
having clinical usefulness when it meets the following characteristics: valid, reliable, responsive, 
and able to be interpreted. The meaning of clinical utility is further explained as questionnaires 
having the capacity to be conducted in a simple and quick manner, easy to score/interpret, and 
provide useful information (Chen, Li, & Kochen, 2005; King et al., 2016; Lauzon et al., 2013). 
However, barriers to routine clinical use of HRQoL questionnaires include cost, feasibility, and 
clinical relevance (Chen et al., 2005).  
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8. Conclusion  
 The literature review conducted highlighted personal and environmental factors that can 
serve as barriers and enablers for brain tumour patients when completing HRQoL questionnaires, 
which may affect participation. However, as explained earlier, brain tumour patients experience 
a variety of symptoms and acquire different levels of cognitive capacity that may also hinder 
successful execution of completing HRQoL questionnaires within the parameters set by their 
standardized contexts. With limited studies on the clinical utility of HRQoL questionnaires in 
brain tumour patients, a feasibility study to compare three commonly used questionnaires 
(EORTC QLQ C-30 and QLQ BN20, FACT-Br, and SF-36 Health Survey) is required to 
understand the clinical usefulness of each one. This will facilitate identification of a HRQoL 
questionnaire that may be the most effective and efficient questionnaire for brain tumour patients 
undergoing neurosurgical treatment.  
 Due to the multiple factors that contribute to clinical utility, we propose to focus on 
evaluating brain tumor patients’ perspectives on constructs that were suggested to be important 
influencers in the clinical usefulness of HRQoL questionnaires in brain tumour patients (Ahlner-
Elmqvist et al., 2009; Lauzon et al., 2013; Walker et al., 2003). These factors consist of the 
following criteria: (1) relevance, (2) ability to highlight most concerns, (3) ease of language, (4) 
time to complete, and (5) assistance required. We also propose to investigate health clinicians’ 
attitudes towards the clinical utility of questionnaires to further assess the usefulness of the three 
HRQoL questionnaires. Criteria to be explored were based on factors that contribute to clinical 
usefulness (Chen et al., 2005). These factors include the following items: (1) relevance of 
information, (2) usefulness of data, and (3) ability to predict a patient’s participation in activities. 
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 This study aims to investigate the feasibility of comparing three commonly used HRQoL 
questionnaires to identify the most effective and efficient tool for brain tumour patients 
undergoing neurosurgical treatment. Evaluating its clinical utility aims to explore possible 
barriers and enablers in the completion of HRQoL questionnaire with brain tumour patients in 
order to provide support that facilitate participation in this activity.  
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Abstract  
 
Purpose: The purpose of this study is to investigate the feasibility of comparing three HRQoL 
questionnaires to identify which is the most effective and efficient tool for brain tumour patients 
undergoing neurosurgical treatment. This study aims to investigate the following questions: (1) 
Is it feasible for brain tumour patients to compare three HRQoL questionnaires before and after 
neurosurgical treatment? If so, (2) Which of the three HRQoL questionnaires is perceived to be 
the most effective by both brain tumour patients and health care professionals? 
 
Methods: A pilot study was conducted in a metropolitan private medical center in Sydney. 
Participants (n=5) were recruited through convenience sampling and were asked to complete 
three HRQoL questionnaires. The usefulness of the European Organisation for Cancer and 
Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) and (QLQ-BN20), the Functional 
Assessment of Cancer Therapy-Brain (FACT-Br), and the Short Form 36 (SF-36) health survey, 
were assessed before and after neurosurgical treatment. Participant and clinician perceptions of 
the tools’ utility were investigated by pre-developed questionnaires. HRQoL tools and 
questionnaires were provided to participants before surgery; and either at their postsurgical 
consultation or by mail.   
 
Results: FACT-Br was the questionnaire well-received by participants. However, varying levels 
of fatigue contributed to the incompletion of assessments.   
 
Conclusion: The FACT-Br was the preferred HRQoL tool in addressing patient concerns in this 
small study following brain tumour surgery. Further studies with a larger sample size are 
recommended to further investigate the clinical utility of HRQoL questionnaires for brain tumour 
patients.  
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Measuring Quality of Life Following Neurosurgical Treatment 
for Brain Tumour Patients: A Feasibility Pilot Study 
 
  Keywords: Quality of Life, Brain Tumour, neurosurgical treatment, patient perspectives 
 
1. Background  
Primary brain tumours in Australia have an annual incidence of 11.3 cases per 100,000 person-
year, within this demographic, there has been a significant increase in primary malignant brain 
tumours [1]. Although primary brain tumours present to have fairly low incidence rates 
compared to other cancer sites, such as breast and lung cancer, brain tumour is a disease 
characterized by severe symptoms and poor prognosis [2-4]. Adults facing this diagnosis are 
often presented with symptoms such as headache, seizures, insomnia, and nausea [5]. They can 
also experience secondary symptoms such as personality changes, cognitive deficits, or aphasia 
due to neurologic deterioration [6, 7]. Patients with malignant brain tumours have poor prognosis 
as these tumours are associated with progressive disability and decline in mental health status [2, 
6]. As advances in anti-cancer treatment focuses on prolonging survival, these treatments still 
pose risks of severe side effects that may be affecting a patient’s quality of life [8, 9]. Therefore, 
there has been an emphasis in looking beyond a patient’s overall survival and measuring clinical 
benefits of any new treatment by obtaining patient perspectives through HRQoL questionnaires 
to ensure that treatments minimize risks and maximize treatment outcomes [9, 10].  
 
Health- related quality of life (HRQoL) questionnaires are subjective measurements that evaluate 
a person’s functional, psychological, and social well-being [11]. Many authors have 
hypothesized that HRQoL data is relevant in acquiring patients’ perspectives and incorporating 
them in treatment plans, with a view to taking a client-centered approach on patient care [8]. 
These tools are used with cancer patients as it can facilitate assessment of treatment needs, 
evaluation of treatment outcome, and prediction of response to future treatment [12]. This is vital 
for brain tumour patients as incorporation of their perspectives in their treatment plan can best 
inform health clinicians how to support the individual, which facilitate better health outcomes.  
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Three common HRQoL questionnaires used for brain tumor patients are: the European 
Organisation for Cancer and Treatment of Cancer (EORTC) Quality of Life Questionnaire 
(QLQ-C30) with the brain cancer-specific subscale (QLQ-BN20) [13, 14]; the Functional 
Assessment of Cancer Therapy-Brain (FACT-Br)  [15]; and the 36-Item Short Form (SF-36) 
health survey [16]. EORTC QLQ BN-20 and FACT-Br are brain cancer specific modules 
developed to complement their core questionnaires (EORTC QLQ-C30 and FACT-G) to address 
the most relevant issues brain cancer patients’ experience. These questionnaires are widely used 
and have been tested for reliability and validity with patients with brain tumours [14, 15, 17, 18].  
Each questionnaire offers a different emphasis on well-being. The EORTC QLQ C-30 and QLQ-
BN20 questionnaires have a focus on patients’ functional concerns [19]. FACT-Br, in 
conjunction with FACT-G, has a psychosocial focus; evaluating the emotional and social 
concerns of brain tumour patients [19]. SF-36 health survey assesses broader physical and 
emotional health domains, which can facilitate a comparison of HRQoL within the general 
population [18]. Despite the differences, these questionnaires aim to obtain patient perspectives 
in order to inform clinicians how a diagnosis or a treatment have influenced a patient’s quality of 
life.  
 
However, research has shown that there has been a significant issue with completing HRQoL 
questionnaires in clinical trials for the brain tumour population [20]. Several studies have 
highlighted methodological and patient related factors that may be contributing to failed 
completion of these questionnaires [8, 21]. In addition to that, several studies have investigated 
difficulties health care professionals have in interpreting HRQoL data [22-24]. At present, no 
single gold standard tool exists to measure HRQoL [25]. Therefore, further investigation is 
required to identify the most effective and efficient HRQoL questionnaire for brain tumour 
patients. This study investigates the feasibility of comparing three commonly used HRQoL 
questionnaires to identify the most effective and efficient tool for brain tumour patients 
undergoing neurosurgical treatment. The research questions are: (1) Is it feasible for brain 
tumour patients to compare three HRQoL questionnaires before and after neurosurgical 
treatment? If so, (2) Which of the three HRQoL questionnaires is perceived to be the most 
effective by both brain tumour patients and health care professionals? 
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2. Methods 
 
2.1 Study Design, Recruitment, and Eligibility  
 
The pilot feasibility study received ethical approval from the study center’s Human Research 
Ethics Committee as an amendment to HREC Reference Number: 5201600915 on July 27th, 
2018.   
A convenience sampling method was used to recruit potential participants at a metropolitan 
private medical center, from August to September 2018. Patients over the age of 18 years 
scheduled to undergo neurosurgical treatment were referred to the first and second author by 
treating neurosurgeons. Eligibility required potential participants to (1) speak and understand 
functional English; (2) have no severe disability that will prevent them from filling out 
questionnaires; (3) provide written informed consent. The first and second author coordinated to 
see potential participants where they acquired a written informed consent before starting the 
study. Participants were informed that their participation in the study was entirely voluntary and 
that they could withdraw their consent at any time. Participants were also informed that there 
would be no change in their clinical treatment nor service by participating or withdrawing from 
the study. 
Patients were identified by a study number in order to correctly match data for before and after 
neurosurgical treatment. Medical records were accessed, after informed consent, to acquire date 
of birth and brain tumour diagnosis to ensure accuracy of patient information.  
 
2.2 Instruments  
 
2.2.1 EORTC QLQ C-30 and EORTC QLQ-BN20 HRQoL Questionnaire 
 
The EORTC QLQ C-30 is a 30-item questionnaire internationally validated for cancer patients 
[17]. This questionnaire consists of five function scales: physical, role, emotional, social, and 
cognitive functioning. These questions are rated on a numeric scale from 1 (Not at All) to 4 
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(Very Much). The last two questions have items assessing overall health and overall quality of 
life. Each of these two questions can be scored on the numeric scale from 1 (Very Poor) to 7 
(Excellent).  
 
The EORTC QLQ Brain Cancer Specific Module (BN20) is a disease specific instrument 
validated for patients with primary brain tumours [14]. It consists of 20 questions investigating 
symptoms experienced in the past week. Each question item is rated on a numeric scale from 1 
(Not at all) to 4 (Very Much). EORTC QLQ-BN20 is commonly used in combination with the 
EORTC QLQ-C30, especially in clinical trials with brain metastases patients [26].  
 
2.2.2 FACT-Br HRQoL Questionnaire 
FACT-Br is a 50-item questionnaire, which consists of both FACT- General (G) and the 
supplementary brain-cancer specific instrument. This questionnaire has been validated for 
primary brain tumour patients and used in clinical studies with brain metastases patients [15, 27]. 
The section with FACT-G investigates 4 components (physical well-being, social/family well-
being, emotional well-being, and functional well-being), while the brain specific subscale lists 
additional concerns. These questions are rated on a numeric scale from 0 (Not at all) to 4 (Very 
much).  
2.2.3 SF-36 Health Survey 
SF-36 Health Survey is a generic health questionnaire with 36 questions which evaluate: 
physical functioning, physical aspects, pain, vitality, social functioning, and emotional concerns. 
It has shown to be both reliable and valid for brain tumour patients [18]. This instrument is rated 
on a numeric scale and presents in seven different forms: 1 (Excellent) to 5 (Poor); 1 (Much 
better now than one year ago) to 5 (Much worse now than one year ago); 1 (Yes, limited a lot) to 
3 (No, not limited at all); 1 (All of the time) to 5 (None of the time); 1 (Not at all) to 5 
(Extremely); 1 (None) to 6 (Very Severe); and 1 (Definitely true) to 5 (Definitely False). 
 
2.2.4 Development of Critique Questionnaire for Participants  
The critique tool developed for brain tumour patients was based on constructs that were 
suggested to be important influencers in the clinical usefulness of HRQoL questionnaires. 
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Relevance of information and ability to highlight disease-specific concerns were seen as vital 
components in HRQoL questionnaires in order to facilitate compliance in filling in such 
questionnaires [22, 28]. Other questions were also developed based on methodological factors 
that were suggested to be possible barriers to completing HRQoL questionnaires such as ease of 
language, time, and assistance to complete these tools [21]. Construction of questions for the 
critique tool followed guidelines outlined by O’Leary in order to promote clarity and specificity 
[29]. The questionnaire was then reviewed by an occupational therapist specializing in neuro-
oncology in order to identify problematic questions.  
 
The critique questionnaire has five multiple choice questions, which incorporates factors that 
contribute to completion of HRQoL questionnaires. These factors, indicative of the usefulness of 
a HRQoL questionnaire, are listed on Table 1. Response categories were listed as “Assessment 
1,” “Assessment 2,” and “Assessment 3”. An open-ended question at the end of the questionnaire 
(“Other Comment”) was included in order to identify other issues that may not be addressed in 
the questionnaire and enable participants to express their true feelings in case the response 
categories do not exactly represent their opinion [29, 30].  
 
Table 1. Questions in critique questionnaire for participants 
Question Number Question 
1 Which set of questions did you find the easiest to understand? 
2 Which set of questions addressed most of your concerns? 
3 Which set of questions took the least time to complete? 
4 Which set of questions do you think is most relevant to you? 
5 Which set of questions required little to no assistance to complete?  
 
2.2.5 Cognitive Competence Rating for Participants 
 
Measurement of neurocognitive function in brain tumour patients was essential as palliative care 
studies have shown that the presence of a cognitive impairment influences both a patient’s ability 
to complete questionnaires and results of HRQoL data [28, 31]. Therefore, using a standardized 
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test for cognitive testing has become standard practice in brain tumour clinical trials [32]. Due to 
the pilot nature of this study and its restricted time and resources, performing a standardized 
cognitive test was not possible. To account for the participant’s cognitive capacity, a cognitive 
competence Likert scale from 0 (Poor) to 4 (Excellent) was developed. This was rated by a 
treating doctor or neuropsychologist before and after neurosurgical treatment.  
2.2.6 Critique Questionnaire for Health Care Professionals  
The critique tool developed for health care professionals contained three items: relevance of 
information, usefulness of data, ability to predict a patient’s participation in activities. Criteria 
developed were based on factors that contribute to clinical usefulness of quality of life measures 
[33]. Usefulness of a HRQoL questionnaire is defined as an instrument’s ability to be conducted 
in a simple and fast manner, while providing important clinical data [33]. Each criteria had 
“Assessment 1,” “Assessment 2,” and “Assessment 3” as subheadings where a 5-point Likert 
scale was used to rate the extent in which they have experienced each criteria. The attitudinal 
scales were listed as (0=Not at all to 5 = Extremely; 0=Not Useful to 5 = Extremely Useful; 
0=Not Relevant to 5 = Extremely Relevant). 
 
 
3. Data Collection  
 
3.1 Participants  
Considering the pilot nature of this study and variability of postsurgical consultations in this 
context, a sample size of (n=5) was obtained. Order of assessments was randomized using a 
computer program. This program generated randomized order of questionnaires for each 
participant, which was used to prepare premade packets. Participants were provided the 
questionnaires before neurosurgical treatment, which were around one to two days depending on 
when participants were admitted to the hospital. Participants were also given the questionnaires 
after their neurosurgical treatment either on their postsurgical consultation or by post. The 
researchers delivering the questionnaires were trained in how to administer the HRQoL 
questionnaires and provide instructions to ensure all participants fill out the questionnaires based 
on the randomized order they were given. The time taken to complete each HRQoL 
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questionnaire was recorded by the researcher. Each participant also received instructions to fill 
out the critique questionnaire after completing all three HRQoL tools. One participant (n = 1) 
completed the questionnaires at their postsurgical consultation, while the rest (n = 4) were sent 
by post.  
3.2 Health Care Professionals  
Questionnaires developed were sent to a neurosurgeon and an occupational therapist (n=2) by 
email invitation. Follow-up emails were sent every two weeks after initial invitation.  
3.3 Data Analysis  
Descriptive statistics (means, standard deviations) were calculated on Excel (Version 1803). 
Statistical comparisons were not made due to lack of randomization, small sample size, and 
change of delivery in instruments before and after surgery.  
 
 
4. Results 
4.1 Participants 
 
Five participants consented to this study (four women and one man, mean age = 49.2, SD= 
13.102). See Table 2 for participants’ demographic details and wide range of brain tumour 
diagnosis. Cognitive competence before and after surgery stayed consistent for all participants 
except one, this participant scored 2 before and 0 after surgery (Participant 2).  
4.1.1 Pilot Testing 
 
Four out of five consenting participants attempted to complete the questionnaires before surgery. 
Each participant had clinical procedures requiring their time and concentration in preparation for 
their surgery, therefore questionnaires were delivered at different times of the day, depending on 
the participant’s availability.  
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Three out of five participants who were diagnosed with high grade brain tumours and brain 
metastases were given the questionnaire the night before their surgery (Participant 1, 2, 3). These 
participants gave different amounts of participation in completion of questionnaires due to  
 
Table 2. Participants’ demographics, brain tumour diagnosis, cognitive competence  
 
 
fatigue levels. Participants were also observed to acquire support from their partners/carers 
during the session. One participant did not participate in completing the questionnaires as the 
 
Participant 
1 
Participant 2 Participant 3 Participant 4 Participant 5 
Mean 
(Standard 
Deviation) 
Gender Female Male Female Female Female 
-
- 
Age (years) 45 59 56 28 58 
49.2 
(13.103) 
Tumour(s) 
Diagnosis 
Anaplastic 
Astrocyto
ma (WHO 
Grade III 
Glioma) 
Glioblastoma
, IDH-WILD 
TYPE 
Brain lesion, 
left temporal 
lobe – 
metastatic 
breast 
carcinoma 
Astrocytoma 
Meningothelial 
Meningioma 
and Secretory 
Meningioma 
(WHO Grade 
I) 
-  
(WHO Grade 
IV) 
(WHO 
Grade II) 
 
 
Cognitive 
Competence 
4 2 4 4 4 - 
Before 
Surgery 
 
4 0 4 4 4 - 
Cognitive 
Competence 
After 
Surgery 
Page 13 of 24 
 
patient reported he ‘felt too tired’ (Participant 2). This patient’s partner reported that he had 
several clinical tests throughout the day and needed to rest. Another participant did not finish all 
three HRQoL questionnaires and only completed the first two they were given (SF-36 and 
FACT-Br) (Participant 1). The researcher observed the participant getting fatigued as she placed 
her head on the table. Participant 1 was given time to rest and rated the critique tool based on the 
two questionnaires she completed. The researcher administered the critique tool as a semi-
interview to facilitate the process. The other two participants diagnosed with low grade brain 
tumours completed their questionnaires independently in the afternoon of the day before their 
surgery.  
 
Post-op questionnaires were delivered by postsurgical consultation (n = 1) or by post (n=4). 
Participant 1 completed the questionnaires on her follow up appointment and successfully 
finished two questionnaires (EORTC QLQ-C30 and QLQ-BN20, FACT-Br). Similar 
observations were made for this patient in comparison to her capacity to complete questionnaires 
before surgery. The patient was observed discussing questions with her partner and reported 
feeling ‘tired’ by the end of the second questionnaire. The researcher delivered the critique tool 
as a semi-interview. The remaining post-op questionnaires were sent by post and two responses 
were obtained from Participant 4 and 5.  
 
4.1.2 Time Taken 
The average time each participant took to complete questionnaires are presented on Table 3. The 
average time the participants took for each questionnaire were within the average 5 to 15 
minutes, which is the standard time HRQoL questionnaires would normally take [34]. The 
researcher was unable to record time for Participant 5 due to interruptions by other health 
clinicians needing to see the participant. However, this participant was still able to finish all three 
questionnaires.  
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Table 3. Average time to complete HRQoL questionnaires  
 Participant 1 Participant 2 Participant 3 Participant 4 Participant 5 
Average (minutes) 13 - 10.33 4 - 
Standard Deviation 0 - 1.53 0 - 
 
 
 
4.1.3 Preferred Tool  
 
Table 4 demonstrates the frequency of HRQoL questionnaire per clinical utility criteria. The total 
does not equate to the number of participants (n=5) per question criteria due to varying levels of 
participation and completion of questionnaires. However, FACT-Br was the questionnaire well-
received under the criteria address most of your concerns and most relevant. HRQoL 
questionnaires chosen per question criteria can be found in Table 5.  
 
Table 4. Frequency of HRQoL questionnaire per clinical utility criteria (before /after 
Neurosurgery) 
 
Question 
Criteria 
Number of participants  
EORTC C-30  
and BN-20 
FACT-Br SF-36 
Pre-op Post-Op Pre-Op Post-Op Pre-Op` Post-Op 
Easiest to 
understand 
- 3 2 1 2 - 
Addressed 
most of 
concerns 
- 1 3 2 - - 
Least time 2 - 2 2 - - 
Relevant - 2 3 1 - - 
No/Little 
assistance 
2 3 - 2 2 1 
Total 4 9 10 8 4 1 
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Participant 3 omitted the questions that asked about relevance and addressed most of your 
concerns when answering the questionnaires before her surgery. She commented on FACT-Br 
and reported that asking about the last seven days is not representative of her experience. 
Participant 3 also reported that some topics such as toileting do not pertain to her as those 
physical concerns are more apparent in a different age group. Similarly, Participant 4 reported 
that a lot of the physical concerns in the questionnaires do not pertain to her as she thought with 
her age, emotional concerns are more relevant. 
 
 
Table 5. Participants’ preferred HRQoL questionnaire based questionnaire criteria (before /after 
neurosurgical treatment) 
 
 
 
 
 
Pre-Op Post-Op Pre-Op Post-Op Pre-Op Post-Op Pre-Op Post-Op Pre-Op Post-Op
EORTC 
C30 and 
BN20
EORTC 
C30 and 
BN20
SF-36
EORTC 
C30 and 
BN20, 
FACT-Br, 
SF-36
---
---
EORTC 
C30 and 
BN20
FACT-Br---FACT-Br
FACT-Br
FACT-Br
EORTC 
C30 and 
BN20
FACT-Br 
EORTC 
C30 and 
BN20 
FACT-Br, 
EORTC 
C30 and 
BN20
EORTC 
C30 and 
BN20, 
FACT-Br
SF-36 
FACT-Br 
FACT-Br 
FACT-Br 
SF-36  
SF-36
-
FACT-Br
-
Which set of questions 
required little to no 
assistance  to complete? 
-
Which set of questions do you 
think is most relevant  to you? FACT-Br - - -
EORTC 
C30 and 
BN20,    
SF-36
EORTC 
C30 and 
BN20
FACT-Br 
EORTC 
C30 and 
BN20
Which set of questions took 
the least time  to complete?
EORTC 
C30 and 
BN20
Which set of questions 
addressed most of your 
concerns ?
FACT-Br - - -
FACT-Br, 
EORTC 
C30 and 
BN20
-FACT-Br 
FACT-Br
Which set of questions did 
you find easiest to 
understand ? 
Questions
Participant 1 Participant 2 Participant 3 Participant 4 Participant 5
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4.2 Health Care Professionals 
 
An occupational therapist specializing in neuro-oncology responded to the questionnaire 
delivered by email. The health clinician’s attitude towards the HRQoL questionnaires and its 
usefulness, relevance, and ability to predict participation are exhibited on Table 6. The health 
care professional rated FACT-Br and EORTC QLQ C-30 and BN 20 similarly as it is both very 
useful and extremely relevant. All three questionnaires however, were rated similarly in its 
ability to predict participation in everyday activities.  
 
Table 6.  Health clinician’s attitude towards usefulness, relevance, ability to predict participation 
HRQoL 
Questionnaires 
 
Usefulness Relevance Predict Participation 
EORTC QLQ  C-30 
and BN20 
 
Very Extremely Moderately 
FACT-Br Very Extremely Moderately 
 
SF-36 Moderately Moderately Moderately 
 
 
Overall, participants who completed the questionnaires reported preferring FACT-Br as the 
HRQoL tool that is the most relevant and have fulfilled the criteria address most of your 
concerns. The health professional that responded stayed consisted with that finding as the health 
professional reported FACT-Br as a very useful and extremely relevant questionnaire for brain 
tumour patients.  
 
5. Discussion 
 
HRQoL questionnaires have become a pertinent outcome measure for brain tumour patients as 
current treatment options pose risks of severe side effects [8]. Therefore, there has been an 
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emphasis in looking beyond a patient’s overall survival and acquiring clinical endpoints that 
assess a person’s quality of life. However, studies have reported a high rate of non-compliance 
for completing HRQoL questionnaires in the brain tumour population [20]. With limited studies 
on the clinical utility of HRQoL questionnaires in the brain tumour population, further 
investigation is required to find the most effective and efficient HRQoL questionnaire for brain 
tumour patients undergoing neurosurgical treatment. We investigated the feasibility of 
comparing three commonly used HRQoL questionnaires (EORTC C30 and BN-20, FACT-Br, 
and SF-36 Health Survey) to identify the most effective and efficient questionnaire for brain 
tumour patients before and after neurosurgical treatment.  
 
The primary aim of this study was to investigate the feasibility of comparing three commonly 
used quality of life questionnaires with brain tumour patients before and after neurosurgical 
treatment. Based on our findings, participants diagnosed with low grade brain tumours were able 
to complete the three HRQoL questionnaires and the critique tool independently and within the 
standard time. Despite the interruptions experienced by Participant 5, questionnaires were still 
completed. This suggests that it is feasible to compare three HRQoL questionnaires for low 
grade brain tumour patients undergoing neurosurgical treatment.  
 
The secondary aim of this study was to identify which of the three HRQoL questionnaire is 
perceived to be the most effective by both brain tumour patients and health care professionals. 
The findings of this study demonstrated that the FACT-Br was chosen as the preferred 
questionnaire for the criteria of “most relevant” and “address most of your concerns.” The 
FACT-Br evaluates subscales of physical, social/family, emotional, functional well-being, and 
brain-specific concerns. In contrast, EORTC C-30 and BN20 evaluates subscales of visual 
disorder, motor dysfunction, future uncertainty, and communication deficit. Our study found, 
FACT-Br and EORTC C-30 and BN20 were chosen for various criteria as the preferred HRQoL 
questionnaires before and after neurosurgical treatment by the participants. This may be due to 
the brain cancer-specific subscales of both FACT-Br and EORTC QLQ BN20, which were 
developed for the purpose of evaluating HRQoL of brain tumour patients [14, 15]. Therefore, 
items in these questionnaires may be a better representation of important topics for brain tumour 
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patients. However, FACT-Br was still chosen to be the preferred tool, which may be due to the 
emotional and social concerns it is able to address. Participant 4, for example, reported that a lot 
of the physical concerns in the questionnaires do not pertain to her as she thinks with her age, 
emotional concerns are more relevant. This may also be a reason as to why SF-36 Health Survey 
was not chosen for the criteria “most relevant” and “address most of your concerns” by 
participants in this study. One study that assessed SF-36 for its reliability and validity for brain 
tumour patients found that it had low sensitivity when assessing functional and emotional status 
[18]. Therefore, questions in SF-36 may not have addressed all of the concerns brain tumour 
patients are experiencing at this point of their diagnosis.  
 
FACT-Br has been tested for its validity for brain metastases patients [27], Participant 3, who 
was treated for metastatic brain cancer, did not choose any assessments pre-operatively under the 
criteria “most relevant” and “address most of your concerns.” Participant 3 did report that 
questioning her quality of life for the past seven days was not representative of her experience. 
Both FACT-Br and EORTC C-30 and BN20 both present their recall period as seven days, 
which may have contributed to the omission of the questions. Omission of questions and 
incompletion of HRQoL questionnaires were factors affecting the collection of data in this study, 
which many authors often assume is due to personal factors, such as having lower function [28].  
 
The findings of this study suggest that patients diagnosed with high grade tumours had high 
levels of fatigue contributing to missing data when acquiring HRQoL questionnaires. These 
participants were also observed to acquire support from their partners/carers. One study assessed 
issues around missing data when collecting HRQoL questionnaires from glioma patients in 
clinical trials and found administrative failure, such as when the questionnaire is administered, to 
be a major source of failure to complete questionnaires [21]. Researchers in quality of life 
assessments have agreed to this finding as they have also found personal factors to be less of an 
issue than administrative, methodological, and logistic factors [35, 36]. Personal factors consist 
of a patient’s motivation, ability to understand instructions, and fill out questionnaires [21]. 
Motivation to participate in this study by filling out the questionnaires was present in all of the 
participants as they all consented to fill out the tools. Some of the participants made an attempt to 
fill out the tools, but were not able to complete the questionnaires independently and so, they 
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sought support from their partners to complete them. Participant 2 demonstrated willingness to 
participate in the study as he consented, however refused to complete the questionnaires due to 
fatigue, which may have acquired from various clinical tests he performed throughout the day. 
This confirmed the issue that administrative factors, such as timing of assessments, that may be 
contributing to incomplete sets of data.  
 
Optimal timing of delivering HRQoL questionnaires are dependent on its purpose [25]. This 
study gathered pre-operative patient perspectives on HRQoL questionnaire to gain baseline 
measurements. However, the administration of the assessments were dependent on the 
availability of patients admitted into the hospital. Participant 1, 2, and 3 were not available until 
the night before their surgery due to neuropsychological assessments and other clinical tests. 
Issues around administering questionnaires immediately after clinical tests contribute to fatigue 
and may also change the attitude of patients in taking HRQoL questionnaires [25]. This may 
have influenced Participant 1, 2, 3’s ability to complete the questionnaires. 
 
Personal factors are perceived as less of an issue when it comes to filling out questionnaires due 
to the apparent motivation seen in patients [35, 36]. For example, a longitudinal HRQoL study 
(n=297) was done to evaluate patients with malignant disease to investigate non-compliance 
during the study and found a high proportion of their participants were able to fill in HRQoL 
questionnaires until death [28]. This study suggested that having more support from family or 
caregivers when filling out questionnaires may facilitate compliance [28]. However, these 
suggestions were based on a positive bias due to the other participants (n =180) who were 
eligible, but did not participate in the study due to having more advanced diseases and were 
closer to death [37]. Therefore, observations were not made for these patients and were not 
represented in the results. The findings of the study were consistent with Participant 2, who was 
diagnosed with a higher grade of brain tumour and was not able to fill out questionnaires before 
and after surgery, despite having support from his partner to fill out the HRQoL tools.  
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6. Implications  
 
From our knowledge, this is the first study that investigated the feasibility of comparing three 
commonly used HRQoL questionnaires (EORTC C30 and BN-20, FACT-Br, and SF-36 Health 
Survey) to identify the most effective and efficient questionnaire for brain tumour patients before 
and after neurosurgical treatment. Findings of this study identified FACT-Br as the preferred tool 
under the criteria most relevant and address most of your concerns. This finding suggests that the 
participants in this study found emotional and social domains to be the relevant issues that is 
representative of their concerns. This finding also stayed consist with the health care 
professional, who identified FACT-Br as a questionnaire that is very useful and extremely 
relevant for brain tumour patients. Another finding of this study found that it is feasible to 
compare the three commonly used questionnaires to low grade brain tumour patients undergoing 
neurosurgical treatment. This was demonstrated to their capacity to complete questionnaires 
independently and in a timely manner. The last finding of this study found patients diagnosed 
with high grade tumours experience high levels of fatigue, either from their diagnosis or 
environmental factors (e.g. neuropsychological exams and other clinical tests), contributing to 
incompletion of HRQoL questionnaires. Participants were also observed to acquire support from 
their partners when filling out the questionnaires as they discussed the content and had their 
partners fill out the questionnaires. This suggests that acquiring a patient-proxy perspective can 
enable involvement of those participants who have difficulties providing self-report 
questionnaires due to fatigue levels.  
 
7. Limitations and Future Studies 
 
There were several limitations to our study. One main limitation is our small sample size 
recruited through convenience sampling in one location. This used a non-randomized and non-
controlled sample, which is a threat to internal validity by not accounting for external factors. 
Although results of this study found feasibility with low grade brain tumour patients, they cannot 
be extrapolated to all other clinical sites. Further studies with a larger sample size are 
recommended to further investigate the usefulness of HRQoL questionnaires.  
 
Page 21 of 24 
 
Due to the pilot nature of this study, systematic procedures in a neurooncological setting were 
not accounted for in the design and time constriction of this project. Therefore, with limited time 
and resources, there was a change of instrument administration (e.g. self-administered 
questionnaire at hospital to questionnaire mailed by post) before and after surgery, which may 
have contributed to the different amounts of missing data before and after neurosurgical 
treatment. Therefore, further studies should administer the questionnaires either by self-report or 
semi interview to enable better delivery of instructions and support if needed. The exclusion 
criteria for this study prevented participants who may have severe cognitive deficits to 
participate, creating a sample bias. Therefore, results of our study does not represent all brain 
tumour patients.  
Based on our findings, further studies should also continue to develop the critique questionnaire 
to further assess clinical utility. For example, the critique tool for health care professionals can 
further expand on the criteria usefulness by assessing how long it takes to calculate and interpret 
HRQoL questionnaires.  Also, due to the observed support some participants had, future studies 
should look into developing a critique tool for patients’ partner/carer (proxy). This may enable 
involvement of those participants who have difficulties providing self-report questionnaires due 
to fatigue levels or possible cognitive deficits.  
 
8. Conclusion 
This pilot study has shown that comparing three commonly used HRQoL questionnaires 
(EORTC QLQ C30 and BN20, FACT-Br, SF-36 Health Survey) to identify the most efficient 
and effective tool is feasible for low grade brain tumour patients undergoing neurosurgical 
treatment. A larger study is recommended to further investigate the clinical utility of HRQoL 
questionnaires for brain tumour patients. 
 
Based on the findings of this small pilot feasibility study, we recommend several suggestions for 
future studies with a larger sample size. Firstly, we recommend studies to administer the HRQoL 
questionnaires either as a self-report or semi interview before and after neurosurgical treatment 
to provide better delivery of instructions and support if needed. We recommend further 
development of critique tool to increase assessment of questionnaires’ clinical utility. Lastly, 
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future studies should look into developing a critique tool for patients’ proxy to enable 
involvement of those participants who have difficulties completing self-report questionnaires due 
to fatigue or cognitive deficits.  
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